Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On March12, 2018, we announced our financial results for the quarter and year ended December31, 2017.The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
Item 2.02 Regulation FD Disclosure
From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. A copy of this slide presentation, dated March2018, is furnished as Exhibit99.2 to this Current Report on Form8-K.
* * *
The information responsive to Items 2.02 and7.01 of this Form8-K and Exhibits 99.1 and 99.2 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.